Tekla Capital Management
VC Fund
Boston, United States
Tekla Capital Management is a VC fund in Boston focused on Biotechnology and Health Care. Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts, and is currently the investment adviser for two closed-end equity funds, H&Q Healthcare Investors and H&Q Life Sciences Investors. The Funds invest in growth equities, both public and private, in the healthcare and life sciences industries.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Tekla Capital Management invests in
Stages Tekla Capital Management invests in
Countries Tekla Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $10M–$65M
- Series B
- $20M–$156M
- Series C
- $28M–$133M
Investment Focus
Industry
- Biotechnology 38 (72%)
- Health Care 27 (51%)
- Therapeutics 18 (34%)
- Medical 16 (30%)
- Pharmaceutical 11 (21%)
Stage
- Series B 15 (28%)
- Series C 15 (28%)
- Series A 9 (17%)
- Post-IPO Equity 4 (8%)
- Series D 3 (6%)
Country
- United States 32 (60%)
- Switzerland 3 (6%)
- France 2 (4%)
- Canada 1 (2%)
- Iceland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan Kwan
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
|
Jason C. Akus
Senior Vice President, Research
|
Senior Vice President, Research | Total investments: 0 | Find email | |
|
Jenny Fowler
Fund Administration Senior Associate
|
Fund Administration Senior Associate | Total investments: 0 | Find email | |
|
Kolotioloma Silue
Manager of Fund Administration
|
Manager of Fund Administration | Total investments: 0 | Find email | |
William R. Hite
Senior Analyst, Research
|
Senior Analyst, Research | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States. | $132.5M / Series C / Apr 24, 2024 | ||
| The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $91M / Post-IPO Equity / Mar 03, 2023 | ||
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M / Series C / Jan 06, 2023 | ||
| Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $60.5M / Series B / May 10, 2022 | ||
| MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company crating novel therapies, and unlocking the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. | $115M / Post-IPO Equity / Apr 05, 2022 | ||
| Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-definedsubtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene. | $64M / Series B / Feb 10, 2022 | ||
| Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States. | $101M / Series B / Feb 07, 2022 | ||
| HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M / Series C / Nov 29, 2021 | ||
| Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. | $156M / Series B / Nov 29, 2021 | ||
| Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $215M / Series B / Nov 09, 2021 | ||
| See all 53 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tekla Capital Management invest in?
Tekla Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tekla Capital Management's check size?
Tekla Capital Management typically joins rounds of $10M–$65M at Series A, $20M–$156M at Series B and $28M–$133M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tekla Capital Management participates in.
How do I contact Tekla Capital Management?
Public channels for Tekla Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tekla Capital Management?
The team at Tekla Capital Management includes Alan Kwan (Senior Analyst), Jason C. Akus (Senior Vice President, Research) and Jenny Fowler (Fund Administration Senior Associate), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
